Role of race in the pharmacotherapy of XXXX .

@entity1 @entity712 @entity1289 @entity3763 @entity2514
OBJECTIVE: To review the literature assessing the differences in response to @entity1289 ( @entity1289 ) inhibitors and beta-blockers in black @entity1 compared with the response in non-black @entity1 in the management of @entity712 . DATA SOURCES: A MEDLINE search (January 1966-May 2001) was performed using @entity712 , blacks, Negroid race, adrenergic beta-antagonists, and @entity1289 inhibitors as key words. English-language articles were identified. Additional pertinent articles were identified from review of the references of these articles. STUDY SELECTION AND DATA EXTRACTION: All identified references were reviewed. All articles deemed relevant to the subject of this article were included. DATA SYNTHESIS: It has been suggested that the antihypertensive effect of @entity1289 inhibitors and beta-blockers may be less in black @entity1 than in other racial groups. Retrospective reanalyses of major @entity712 trials have suggested that black @entity1 may not realize a significant benefit in morbidity or mortality when @entity712 is managed with @entity1289 inhibitors or beta-blockers. It has also been suggested that black @entity1 may respond more favorably than non-black @entity1 to the combination of @entity2514 and @entity3763 . CONCLUSIONS: Published reanalyses of @entity1289 inhibitor and beta-blocker trials in @entity712 provide weak data to support a lack of benefit in black @entity1 . The published literature on this topic is limited by its retrospective nature. Firm conclusions regarding the influence of race on effectiveness of @entity1289 inhibitors and beta-blockers cannot be made until prospective trials, with planned analysis of the effect of race, have been performed.
